SGLT2 Inhibitors in Diabetes Mellitus Treatment

Author(s): Juan Rosas-Guzman, Juan Rosas-Saucedo, Alma R.J. Romero-Garcia.

Journal Name: Reviews on Recent Clinical Trials

Volume 12 , Issue 1 , 2017

Become EABM
Become Reviewer

Graphical Abstract:


Type 2 Diabetes Mellitus (T2DM) is a chronic illness with high prevalence in Mexico, Latin- America, and the world and is associated to high morbidity, disability, and mortality rate, especially in developing countries. T2DM physiopathology is very complex; insulin resistance in the muscle, liver, and adipose tissue, a reduction in the production of incretins (mainly GLP-1) in the intestine, increased glucagon synthesis, an insufficient response of insulin generation, and increased glucose reabsorption in the kidney lead all together to an hyperglycemic state, which has been closely associated with the development of micro and macrovascular complications. Sodium Glucose Linked Transporter 2 inhibitors (SGLT2i) are the most recent therapeutic class available for treating T2DM. SGLT2i central effect is a glycosuric action, and they can reverse the deleterious effect of tubular reabsorption of glucose in the diabetic patient resulting in greater hyperglycemia. Because their mechanism of action is completely different to current drugs, they can be considered as monotherapy or in combination with any other oral or parenteral medication, including different types of insulin or its analogues. This therapeutic synergy accomplishes a greater percentage of patients achieving glycemic control goals.

Keywords: Advantages, adverse event, antidiabetic therapy, diabetes mellitus, physiopathology, SGLT2 inhibitor.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2017
Page: [8 - 18]
Pages: 11
DOI: 10.2174/1574887111666160829145810
Price: $65

Article Metrics

PDF: 30